title: Properties of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of mammalian ribonucleotide reductase.
abstract: In previous studies, N-hydroxy-N'-aminoguanidine (HAG) derivatives were demonstrated to suppress growth and clonogenicity of tumor cells which correlated with the inhibition of ribonucleotide reductase and DNA synthesis. The present work has focused on the properties of five HAG derivatives as inhibitors of the ribonucleotide reductase from Ehrlich ascites tumor cells. HAG derivatives acted as non-competitive inhibitors of ribonucleotide reductase with respect to the substrates CDP and ADP. The apparent Ki values for the various HAG derivatives as inhibitors of CDP reductase ranged from 3.4 to 543 microM. However, the apparent Ki values for these inhibitors with respect to ADP reductase were 2- to 10-fold lower than the respective values for CDP reductase. After a preincubation of HAG derivatives and ribonucleotide reductase in the absence of substrates, an increased inhibition was observed. The activity of the inhibited enzyme could be restored by passage over a Sephadex G-25 column and subsequent incubation with dithioerythritol. The addition of either the non-heme iron subunit or the effector-binding subunit to the intact enzyme in the assay mixture resulted in a diminished inhibition of ADP reduction. Inhibition by HAG derivatives of ribonucleotide reductase activity in the test tube was not enhanced by iron chelators. However, a combination of HAG compounds and iron chelators synergistically inhibited the growth of L1210 cells.
authors.affiliation: Department of Internal Medicine, College of Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa 33612.
authors.forename: G
authors.initials: G
authors.lastname: Weckbecker
authors.forename: E J
authors.initials: EJ
authors.lastname: Lien
authors.forename: J G
authors.initials: JG
authors.lastname: Cory
mesh_terms: D000588:Amines; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000201:enzymology; D002455:Cell Division / Q000187:drug effects; D004357:Drug Synergism; D006146:Guanidines / Q000494:pharmacology*; D007700:Kinetics; D007939:Leukemia L1210 / Q000473:pathology; D051379:Mice; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
chemical_list: D000588:Amines; D006146:Guanidines; D012264:Ribonucleotide Reductases